Stock Events

Stock Events

Valirx 

GBX0.29
4
-GBX0.03-9.28% Today

Statistics

Day High
0.3
Day Low
0.29
52W High
0.88
52W Low
0.22
Volume
365,664
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10JunExpected
Q1 2023
Q2 2023
Q1 2024
Q2 2024
Q1 2025
Q2 2025
Next
-1.04
-0.71
-0.37
-0.04
Expected EPS
N/A
Actual EPS
N/A

Financials

-3,832%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
5MRevenue
-191.6MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VAL.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.LSE
Mkt Cap194.5B
GSK
GSK.LSE
Mkt Cap71.64B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb, a global biopharmaceutical company, focuses on discovering, developing, and delivering innovative medicines for cancer and other diseases, aligning with Valirx's mission.
Pfizer
PFE
Mkt Cap140.15B
Pfizer's broad range of oncology and biopharmaceutical products makes it a competitor to Valirx, especially in the development of cancer treatments.
Merck
MRK
Mkt Cap214.76B
Merck & Co.'s strong focus on cancer research and therapies, including immunotherapy and targeted treatments, places it in direct competition with Valirx.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG, with its extensive portfolio in oncology and personalized healthcare, competes in the same space as Valirx, particularly in cancer treatment innovations.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, known for its leadership in healthcare and significant investment in research and development in oncology, competes with Valirx in the cancer treatment arena.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie's focus on developing advanced therapies for complex diseases, including cancer, makes it a competitor to Valirx, especially in the area of innovative treatment options.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, with its focus on human therapeutics and strong pipeline in oncology, competes with Valirx in the development of cancer treatments and therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its innovative biotechnology and medical research in oncology, competes with Valirx in the quest to develop novel cancer therapies.

About

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. It has an agreement with University of Dundee. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
Show more...
CEO
Dr. Mark Eccleston M.B.A., Ph.D.
Employees
14
Country
GB
ISIN
GB00BLH13C52

Listings

F
DE
EAJF.F
LSE
GB
VAL.LSE

0 Comments

Share your thoughts

FAQ

What is Valirx stock price today?▼
The current price of VAL.LSE is GBX0.29 GBX — it has decreased by -9.28% in the past 24 hours. Watch Valirx stock price performance more closely on the chart.
What is Valirx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Valirx stocks are traded under the ticker VAL.LSE.
Is Valirx stock price growing?▼
VAL.LSE stock has fallen by -9.28% compared to the previous week, the month change is a -10.12% fall, over the last year Valirx has showed a -47.22% decrease.
When is the next Valirx earnings date?▼
Valirx is going to release the next earnings report on June 10, 2026.
What is Valirx revenue for the last year?▼
Valirx revenue for the last year amounts to 5M GBX.
What is Valirx net income for the last year?▼
VAL.LSE net income for the last year is -191.6M GBX.
How many employees does Valirx have?▼
As of April 01, 2026, the company has 14 employees.
In which sector is Valirx located?▼
Valirx operates in the Health Care sector.
When did Valirx complete a stock split?▼
The last stock split for Valirx was on April 06, 2020 with a ratio of 1:125.
Where is Valirx headquartered?▼
Valirx is headquartered in England, GB.